Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.
Alison M. Edwards
Advertisement
https://www.linkedin.com/in/alison-m-edwards-88801969/
Articles by Alison M. Edwards
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
3
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5